A61P 11 - Drugs for disorders of the respiratory system

Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
12/2002
12/10/2002	US6492516 Pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
12/10/2002	US6492497 Specific binding members for TGFbeta1
12/10/2002	US6492428 Macrophage migration inhibitory factor (mif); substituted iminoquinone or orthoquinone ring systems
12/10/2002	US6492425 Inhibitors of transcription factor-NF-κB
12/10/2002	US6492414 Retinoic acid receptor agonists for the inhibition of alveolar destruction and/or promoting formation of alveoli in lung tissue
12/10/2002	US6492409 Such as 5-(1-(3-aminopropyl)-3-indolyl)-1-(3-indolyl)-1,3-dihydroimidazol-2-one; protein kinase c inhibitors; high solubility; reduced color; treating inflammatory and/or immunological disorders
12/10/2002	US6492408 Peptidomimetic inhibitors of intercellular adhesion molecules binding to leukointegrins, such as lfa-1 and mac-1
12/10/2002	US6492406 Pharmaceutically active compounds
12/10/2002	US6492403 Methods of treating C1s-mediated diseases and conditions and compositions thereof
12/10/2002	US6492396 Substituted thioacetamides
12/10/2002	US6492393 Compounds useful as anti-inflammatory agents
12/10/2002	US6492372 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
12/10/2002	US6492362 Compounds and compositions as cathepsin S inhibitors
12/10/2002	US6492360 Phthalazine derivatives phosphodiesterase 4 inhibitors
12/10/2002	US6492358 For treatment of sexual disorders, male erectile dysfunction
12/10/2002	US6492355 Adamantane derivatives
12/10/2002	US6492348 Adenosine derivatives
12/10/2002	US6492129 Fragments comprising the n-terminal region of connective tissue growth factor (ctgf); screening for inhibitors or stimulators of ctgf
12/10/2002	US6491907 Genetic engineered chimera particles comprising capsids from adeno-associated virus and genome inverted terminal repeat sequences as vectors for supplying and expressing nucleotide sequence in cells
12/10/2002	CA2208792C Substituted indazole derivatives
12/10/2002	CA2121147C Synthetic lung surfactant having antioxidant properties
12/08/2002	CA2817619A1 Methods of administering anti-tnf.alpha. antibodies
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097033A2 Antibodies that immunospecifically bind to trail receptors
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002096952A2 Conjugate of a transport protein and a protein for modulation of notch signalling
12/05/2002	WO2002096911A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators
12/05/2002	WO2002096909A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096879A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096855A2 Anticholinergic compounds and methods of use
12/05/2002	WO2002096467A2 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	WO2002096466A1 Medicinal composition
12/05/2002	WO2002096463A1 A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
12/05/2002	WO2002096462A1 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
12/05/2002	WO2002096458A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	WO2002096457A2 Stable liquid formulations of antibodies
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096423A2 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
12/05/2002	WO2002096422A2 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	WO2002096407A1 Liquid drug preparations
12/05/2002	WO2002096406A1 Medicinal compositions
12/05/2002	WO2002096405A1 Drug preparations
12/05/2002	WO2002096401A1 Solid pharmaceutical formulations comprising modafinil
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096362A2 Method for treating fibrotic diseases or other indications vi
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002065978A3 Functional agent for decomposing nicotine and method of preparing the same
12/05/2002	WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof
12/05/2002	WO2002006453A3 Regulation of human desc1-like serine protease
12/05/2002	WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/05/2002	WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183514 Useful in the treatment and control of solid tumors
12/05/2002	US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183350 Phenanthridine-n-oxides with pde-iv inhibiting activity
12/05/2002	US20020183338 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
12/05/2002	US20020183334 For therapy of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder
12/05/2002	US20020183326 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them
12/05/2002	US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
12/05/2002	US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
12/05/2002	US20020183309 For therapy of acute myocardial infarction, asthma, bipolar disorder, cognitive enhancement, cognitive deficits in psychiatric disorders, cutaneous carcinoma, drug abuse, depression, gastrointestinal disorders, inflammation
12/05/2002	US20020183293 Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage
12/05/2002	US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
12/05/2002	US20020183269 Novel compounds
12/05/2002	US20020182698 Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
12/05/2002	US20020182650 Inhibitors of binding between proteins and macromolecular ligands
12/05/2002	US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect
12/05/2002	US20020182274 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance
12/05/2002	US20020182265 Lubricious coatings for substrates
12/05/2002	US20020182213 Method for the treatment of fibrosis
12/05/2002	US20020182208 Glycosylated antibody
12/05/2002	US20020179087 Pharmaceutical compositions containing an oxitropium salt and a betamimetic
12/05/2002	DE10126924A1 Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability
12/05/2002	CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2448963A1 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	CA2448956A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002	CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	CA2448363A1 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
12/05/2002	CA2448345A1 Stable liquid formulations of antibodies
12/05/2002	CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002	CA2448294A1 Method for treating fibrotic diseases or other indications vi
12/05/2002	CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases

1 ... 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 ... 878